|
US6660753B2
(en)
|
1999-08-19 |
2003-12-09 |
Nps Pharmaceuticals, Inc. |
Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
EP1379525B1
(en)
*
|
2001-02-21 |
2007-10-10 |
Nps Pharmaceuticals, Inc. |
Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
ES2272754T3
(es)
|
2001-04-02 |
2007-05-01 |
Brown University Research Foundation |
Uso de antagonistas mglur5 en la fabricacion de un medicamento en el tratamiento de sindrome x fragil, autismo y retardo mental.
|
|
US6916821B2
(en)
|
2001-04-02 |
2005-07-12 |
Brown University |
Methods of treating disorders with Group I mGluR antagonists
|
|
EP1458383B1
(en)
*
|
2001-12-18 |
2007-11-21 |
Merck & Co., Inc. |
Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
|
|
AU2002366388B2
(en)
*
|
2001-12-18 |
2008-09-18 |
Merck & Co., Inc. |
Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
|
|
JP2005516950A
(ja)
*
|
2001-12-19 |
2005-06-09 |
メルク エンド カムパニー インコーポレーテッド |
代謝型グルタミン酸受容体−５のヘテロアリール置換イミダゾールモジュレータ
|
|
JP4493341B2
(ja)
*
|
2002-03-12 |
2010-06-30 |
メルク・シャープ・エンド・ドーム・コーポレイション |
代謝型グルタメート受容体−５の二アリール置換テトラゾールモジュレータ
|
|
US7964609B2
(en)
|
2002-06-20 |
2011-06-21 |
Astrazeneca Ab |
Use of mGluR5 antagonists for the treatment of gerd
|
|
SE0201943D0
(sv)
*
|
2002-06-20 |
2002-06-20 |
Astrazeneca Ab |
New use
|
|
TW200424183A
(en)
*
|
2002-08-09 |
2004-11-16 |
Nps Pharma Inc |
New compounds
|
|
CN1894241A
(zh)
|
2002-08-09 |
2007-01-10 |
阿斯利康(瑞典)有限公司 |
作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑
|
|
WO2004014902A2
(en)
*
|
2002-08-09 |
2004-02-19 |
Astrazeneca Ab |
Compounds having an activity at metabotropic glutamate receptors
|
|
GB0303503D0
(en)
*
|
2003-02-14 |
2003-03-19 |
Novartis Ag |
Organic compounds
|
|
AU2004227833B2
(en)
*
|
2003-04-04 |
2009-10-01 |
Merck & Co., Inc. |
Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
|
|
JP2006528980A
(ja)
*
|
2003-05-15 |
2006-12-28 |
メルク エンド カムパニー インコーポレーテッド |
Ｓ１ｐ受容体作働薬としての３−（２−アミノ−１−アザシクロ）−５−アリール−１，２，４−オキサジアゾール類
|
|
WO2005060961A2
(en)
*
|
2003-12-18 |
2005-07-07 |
Astrazeneca Ab |
Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
|
|
WO2005061489A1
(en)
*
|
2003-12-24 |
2005-07-07 |
Prosidion Limited |
Heterocyclic derivatives as gpcr receptor agonists
|
|
MY152888A
(en)
*
|
2004-02-18 |
2014-11-28 |
Astrazeneca Ab |
Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists.
|
|
JP2007523181A
(ja)
*
|
2004-02-18 |
2007-08-16 |
アストラゼネカ アクチボラグ |
ポリヘテロ環式化合物、および、代謝型グルタミン酸受容体アンタゴニストとしてのそれらの使用
|
|
US7585881B2
(en)
*
|
2004-02-18 |
2009-09-08 |
Astrazeneca Ab |
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
TW200538108A
(en)
|
2004-02-19 |
2005-12-01 |
Astrazeneca Ab |
Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
WO2006004142A1
(ja)
*
|
2004-06-30 |
2006-01-12 |
Banyu Pharmaceutical Co., Ltd. |
ビアリール誘導体
|
|
KR100621192B1
(ko)
*
|
2004-10-13 |
2006-09-19 |
한국화학연구원 |
무스카린 수용체 작용물질로서 작용하는1,2,3,4-테트라하이드로피리미디닐-1,2,4-옥사다이아졸유도체와 이의 제조방법
|
|
JP4557685B2
(ja)
|
2004-11-15 |
2010-10-06 |
独立行政法人理化学研究所 |
蛍光蛋白質
|
|
CA2593439C
(en)
|
2005-01-14 |
2014-02-25 |
F. Hoffmann-La Roche Ag |
Thiazole-4-carboxamide derivatives as mglur5 antagonists
|
|
GB0510142D0
(en)
*
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds A1
|
|
WO2007001973A1
(en)
*
|
2005-06-28 |
2007-01-04 |
Astrazeneca Ab |
New use
|
|
US8168793B2
(en)
|
2005-07-26 |
2012-05-01 |
Portela & Ca., S.A. |
Nitrocatechol derivatives as COMT inhibitors
|
|
AR058807A1
(es)
|
2005-09-29 |
2008-02-27 |
Astrazeneca Ab |
5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
|
|
BRPI0618636A2
(pt)
|
2005-11-08 |
2011-09-06 |
Hoffmann La Roche |
derivados de tiazolo [4,5-c]piridina
|
|
US7951824B2
(en)
|
2006-02-17 |
2011-05-31 |
Hoffman-La Roche Inc. |
4-aryl-pyridine-2-carboxyamide derivatives
|
|
JP5099005B2
(ja)
*
|
2006-04-03 |
2012-12-12 |
アステラス製薬株式会社 |
ヘテロ化合物
|
|
EP1845097A1
(en)
|
2006-04-10 |
2007-10-17 |
Portela & Ca., S.A. |
Oxadiazole derivatives as COMT inhibitors
|
|
EP2083921A2
(en)
*
|
2006-09-04 |
2009-08-05 |
Neurosearch A/S |
Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
|
|
PL2069336T3
(pl)
|
2006-09-07 |
2013-05-31 |
Idorsia Pharmaceuticals Ltd |
Pochodne pirydyn-4-ylu jako środki immunomodulujące
|
|
AU2007292992B2
(en)
|
2006-09-08 |
2013-01-10 |
Actelion Pharmaceuticals Ltd |
Pyridin-3-yl derivatives as immunomodulating agents
|
|
ES2393412T3
(es)
|
2006-09-21 |
2012-12-21 |
Actelion Pharmaceuticals Ltd. |
Derivados de fenilo y su uso como inmunomoduladores
|
|
PL2481410T3
(pl)
|
2007-01-31 |
2017-03-31 |
Bial - Portela & Ca., S.A. |
Pochodne nitrokatecholu jako inhibitory COMT podawane w określonym schemacie dawkowania
|
|
SI2125797T1
(sl)
|
2007-03-16 |
2014-03-31 |
Actelion Pharmaceuticals Ltd. |
Derivati amino-piridina kot agonisti receptorja s1p1/edg1
|
|
ES2361463T3
(es)
|
2007-08-17 |
2011-06-17 |
Actelion Pharmaceuticals Ltd. |
Derivados de piridina como moduladores del receptor s1p1/edg1.
|
|
EP2215049B1
(en)
|
2007-10-31 |
2019-06-12 |
Merck Sharp & Dohme Corp. |
P2x3, receptor antagonists for treatment of pain
|
|
EP2217594B1
(en)
|
2007-11-01 |
2014-01-08 |
Actelion Pharmaceuticals Ltd. |
Novel pyrimidine derivatives
|
|
SI2234985T1
(sl)
*
|
2007-12-20 |
2012-06-29 |
Bayer Pharma AG |
4-(4-ciano-2-tioaril)dihidropirimidinoni in njihova uporaba
|
|
AU2009212135B2
(en)
|
2008-02-07 |
2014-08-21 |
Massachusetts Eye & Ear Infirmary |
Compounds that enhance Atoh-1 expression
|
|
CA2715317A1
(en)
|
2008-03-07 |
2009-09-11 |
Actelion Pharmaceuticals Ltd |
Novel aminomethyl benzene derivatives
|
|
CL2009000628A1
(es)
|
2008-03-17 |
2010-04-09 |
Bial Portela & Companhia S A |
Forma cristalina de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol, composicion farmaceutica que la comprende, proceso para obtenerla y su uso para tratar trastornos del animo, enfermedad de parkinson y trastornos parkinsonianos, alteraciones gastrointestinales, entre otros.
|
|
US8598209B2
(en)
|
2008-10-31 |
2013-12-03 |
Merck Sharp & Dohme Corp. |
P2X3, receptor antagonists for treatment of pain
|
|
DE102008057344A1
(de)
|
2008-11-14 |
2010-05-20 |
Bayer Schering Pharma Aktiengesellschaft |
Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
|
|
DE102008057364A1
(de)
|
2008-11-14 |
2010-05-20 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte Aryl-Verbindungen und ihre Verwendung
|
|
DE102009041242A1
(de)
|
2009-09-11 |
2011-12-15 |
Bayer Schering Pharma Aktiengesellschaft |
Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
|
|
DE102008057343A1
(de)
|
2008-11-14 |
2010-05-20 |
Bayer Schering Pharma Aktiengesellschaft |
Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
|
|
DE102009041241A1
(de)
|
2009-09-11 |
2011-08-04 |
Bayer Schering Pharma Aktiengesellschaft, 13353 |
Substituierte Aryl-Verbindungen und ihre Verwendung
|
|
EP2411001B1
(en)
|
2009-03-23 |
2018-01-17 |
Merck Sharp & Dohme Corp. |
P2x3, receptor antagonists for treatment of pain
|
|
US9238647B2
(en)
|
2009-03-23 |
2016-01-19 |
Merck Sharp & Dohme Corp. |
P2X3 receptor antagonists for treatment of pain
|
|
EP2410858B1
(en)
|
2009-03-23 |
2016-09-07 |
Merck Sharp & Dohme Corp. |
P2x3 receptor antagonists for treatment of pain
|
|
US9132094B2
(en)
|
2009-04-01 |
2015-09-15 |
Bial—Portela & Ca, S.A. |
Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
|
|
WO2010120741A1
(en)
*
|
2009-04-13 |
2010-10-21 |
Irm Llc |
Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
|
|
WO2011007324A1
(en)
|
2009-07-16 |
2011-01-20 |
Actelion Pharmaceuticals Ltd |
Pyridin-4-yl derivatives
|
|
EP2544688B1
(en)
|
2010-03-02 |
2016-09-07 |
President and Fellows of Harvard College |
Methods and compositions for treatment of angelman syndrome
|
|
UA109804C2
(xx)
|
2011-01-19 |
2015-10-12 |
|
2-метоксипіридин-4-ільні похідні
|
|
US20140045900A1
(en)
|
2011-02-11 |
2014-02-13 |
Bial-Portela & Ca, S.A. |
Administration regime for nitrocatechols
|
|
PT2791134T
(pt)
|
2011-12-13 |
2019-12-18 |
BIAL PORTELA & Cª S A |
Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase
|
|
JP5946288B2
(ja)
*
|
2012-02-24 |
2016-07-06 |
公立大学法人名古屋市立大学 |
新規ヒドロキサム酸誘導体及びその用途
|
|
BR112015019643A8
(pt)
*
|
2013-02-15 |
2019-11-05 |
Monsanto Technology Llc |
compostos de 3,5-dissubstituído-4,5-di-hidro-1,2,4-oxadiazol, composição nematicida aquosa, semente e método para controlar nematódeos indesejáveis
|
|
EP2853532B1
(en)
*
|
2013-09-28 |
2020-12-09 |
Instytut Farmakologii Polskiej Akademii Nauk |
1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
|
|
RU2017120184A
(ru)
|
2014-11-28 |
2018-12-28 |
БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. |
Лекарства для замедления течения болезни паркинсона
|
|
MY192358A
(en)
|
2015-05-20 |
2022-08-17 |
Idorsia Pharmaceuticals Ltd |
Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
|
|
TWI681956B
(zh)
|
2015-06-23 |
2020-01-11 |
日商橘生藥品工業股份有限公司 |
吡唑衍生物或其藥理學上容許之鹽
|
|
ES2975136T3
(es)
*
|
2016-03-30 |
2024-07-03 |
Sinntaxis AB |
Moduladores alost alostéricos negativos de MGLUR5 para uso en el tratamiento de daños cerebrales maduros
|
|
EP3904350B1
(en)
*
|
2018-04-12 |
2023-08-23 |
Bayer Aktiengesellschaft |
N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamide derivatives and the corresponding pyridine-carboxamide derivatives as pesticides
|
|
KR102276327B1
(ko)
*
|
2019-06-25 |
2021-07-12 |
연세대학교 산학협력단 |
신규 옥사다이아졸 화합물 및 이를 포함하는 당뇨 예방 또는 치료용 조성물
|
|
MX2022002597A
(es)
*
|
2019-09-05 |
2022-05-13 |
Trevena Inc |
Métodos de tratamiento de la epilepsia usando los métodos.
|